Effect of Calcium Polystyrene Sulfonate in Prevention and Treatment of Hyperkalemia of Patients with Chronic Kidney Disease Induced by Taking RAAS-I
Objective To explore clinical effect of calcium polystyrene sulfonate in prevention and treatment of patients with hyperkalemia of chronic kidney disease (CKD) induced by taking RAAS-I.Methods 80 cases of patients with CKD treated in our hospital were selected as the study objects, and all the patients were treated with RAAS-I for over 4 weeks, and were divided into observation group and control group randomly.The control group were given conventional treatment, and the observation group were combined with calcium polystyrene sulfonate.Changes of 24 h urine protein, serum creatinine and serum potassium levels before treatment and after treatment of 2 months were figured and observed in the observation group, and blood potassium level in different periods were figured and analyzed in the two groups.Results After treatment, 24 h urinary protein level in the observation group was significantly higher than that before treatment (P<0.05), and serum potassium level was significantly lower than that before treatment (P<0.05).The levels of serum potassium at 1, 3, and 6 months of treatment in the observation group were lower than those in the control group (P<0.05).Conclusion The effect is obvious of calcium polystyrene sulfonate in prevention and treatment of patients with CKD induced by taking RAAS-I, and blood potassium level is well controlled.
NETL
NSTL
万方数据
